Jay P. Patel

发表

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

N. Socci, A. Viale, A. Ferrando, 2012, The New England journal of medicine.

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

O. Abdel-Wahab, J. Zavadil, A. Melnick, 2011, Cancer cell.

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.

E. Pronier, C. Mason, A. Ferrando, 2014, Cell reports.

DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia

Iannis Aifantis, Christopher E. Mason, Jonathan D. Licht, 2014 .

Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis

Mithat Gonen, Christopher E. Mason, Omar Abdel-Wahab, 2012, Nature Genetics.

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

M. Gönen, O. Abdel-Wahab, A. Heguy, 2012, Blood.

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Iannis Aifantis, Omar Abdel-Wahab, Jacob D. Jaffe, 2012, Cancer cell.

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

T. Golub, C. Mermel, B. Ebert, 2014, Blood.

LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro ﬁ ling of hematologic malignancies in the clinical setting

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016 .

How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?

R. Levine, Jay P. Patel, R. Levine, 2012, Hematology. American Society of Hematology. Education Program.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900

O. Abdel-Wahab, R. Levine, J. Bennett, 2018, Haematologica.

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.

J. Teruya-Feldstein, P. Maslak, S. Jhanwar, 2013, Leukemia research.

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

O. Abdel-Wahab, R. Levine, M. Tallman, 2014 .

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

O. Abdel-Wahab, R. Levine, M. Tallman, 2014 .

Device Closure for Stroke with Patent Foramen Ovale

M. Gönen, R. Levine, Jay P. Patel, 2012 .

The role of mutations in epigenetic regulators in myeloid malignancies

O. Abdel-Wahab, R. Levine, A. Shih, 2012, Nature Reviews Cancer.

Conditional Deletion of Asxl1 Results in Myelodysplasia

Jacob D. Jaffe, B. Bernstein, Mazhar Adli, 2012 .

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

E. Estey, M. Gönen, O. Abdel-Wahab, 2014, Leukemia.

Relapse specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

W. Evans, C. Mason, Sheng Li, 2013, Nature Genetics.

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

M. Gönen, O. Abdel-Wahab, A. Melnick, 2012, Blood.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

O. Abdel-Wahab, A. Heguy, R. Levine, 2010, Cancer research.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

D. Gilliland, B. Ebert, M. L. Beau, 2009, Blood.

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition

O. Abdel-Wahab, A. Melnick, R. Levine, 2014, Leukemia.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2016, Blood.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

O. Abdel-Wahab, R. Levine, J. Bromberg, 2010, Blood.

pathway activation in myeloproliferative neoplasm pathogenesis Integrated genomic analysis illustrates the central role of JAK-STAT

T. Golub, B. Ebert, A. Bass, 2014 .

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

O. Abdel-Wahab, R. Levine, J. Bennett, 2016, Blood.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

D. Margolis, O. Abdel-Wahab, K. Yen, 2012, Blood.

mutations and clinical outcome in acute myeloid leukemia Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase

D. Margolis, O. Abdel-Wahab, K. Yen, 2013 .

Title: Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Running Head: 2HG predicts IDH mutations and clinical outcome in AML

Martin, D. Margolis, O. Abdel-Wahab, 2013 .

Cancer Cell ASXL 1 Loss Inhibits PRC 2 in Myeloid Leukemia syndrome and z 10 % – 15 % of patients with myeloproliferative neoplasms and acute myeloid leukemia

Jacob D. Jaffe, B. Bernstein, Mazhar Adli, 2012 .

Minimal Residual Disease Assessment By Flow Cytometry in AML Is an Independant Prognostic Factor Even after Adjusting for Cytogenetic/Molecular Abnormalities

M. Gonen, O. Abdel-Wahab, R. Levine, 2014 .

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

D. Gilliland, O. Abdel-Wahab, W. Vainchenker, 2009, Leukemia.

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

D. Gilliland, O. Abdel-Wahab, R. Levine, 2009, Leukemia.

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

D. Gilliland, O. Abdel-Wahab, R. Levine, 2009, Leukemia.

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

D. Gilliland, O. Abdel-Wahab, A. Heguy, 2010, Leukemia.

The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

O. Abdel-Wahab, O. Kilpivaara, R. Levine, 2010, Leukemia.

DNA Hydroxymethylation P rofiling Reveals that WT 1 Mutations Result in Loss of TET 2 Function in Acute Myeloid Leukemia

E. Pronier, C. Mason, A. Ferrando, 2014 .

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

N. Socci, A. Viale, A. Ferrando, 2010 .

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

T. Golub, C. Mermel, B. Ebert, 2014, Blood.

PHF6 mutations in adult acute myeloid leukemia

A. Ferrando, Á. Payer, F. Speleman, 2011, Leukemia.

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

O. Abdel-Wahab, R. Levine, J. Bennett, 2016, Blood.